Last updated on April 16, 2014 at 17:34 EDT

Latest Helsinn Healthcare Stories

2012-10-15 03:23:48

LUGANO, Switzerland and MELBOURNE, Australia, Oct. 15, 2012 /PRNewswire/ -- Melbourne biopharmaceutical company Specialised Therapeutics Australia (STA) has been granted exclusive commercialisation rights to a new drug for the treatment of NSCLC cachexia-anorexia. This condition is a serious multifactorial disorder which involves muscle wasting and metabolic impairment and commonly affects patients with advanced cancer. STA has reached agreement with Swiss pharmaceutical company...

2010-12-09 04:55:00

COPENHAGEN, December 9, 2010 /PRNewswire-FirstCall/ -- - ZP1846, a Novel GLP-2 Agonist, Continues to Advance in Clinical Development Under Licensing Agreement Zealand Pharma A/S (NASDAQ OMX: ZEAL) ("Zealand Pharma" or "the Company"), a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs that recently listed on NASDAQ OMX, today announces the receipt of a EUR 500,000 (DKK 3.73 million*) milestone payment as part of its license...